Abstract
The PI3K/Akt signaling network regulates cell growth and apoptosis, and its constitutive activation has been implicated in the pathogenesis of a variety of malignancies. Recent studies suggest that PI3K/Akt signaling is frequently up-regulated in blast cells from AML patients and strongly contributes to proliferation, survival, and drug-resistance of these cells. Up-regulation of this network in AML may due to several reasons, including FLT3 and Ras activating mutations, increased levels of PI3K p110δ catalytic subunit, lack of PTEN lipid phosphatase expression, and autocrine production of growth factors. Small molecules designed to specifically target key components of this signal transduction network have been shown to induce apoptosis and/or increase conventional drug sensitivity of AML blasts in vitro. Therefore, these inhibitory molecules are being developed for clinical use either as single therapeutic agents or in combination with other forms of therapy. Nevertheless, PI3K/Akt blockade in vivo might have detrimental systemic side effects, given the multiple physiological roles played by this pathway, such as insulin-dependent glucose transport. Herein, we summarize our knowledge about PI3K/Akt signaling in AML and we highlight several pharmacological inhibitors which could be used in the future for treating this too often fatal hematological disorder.
Keywords: Acute myeloid leukaemia, signal transduction, 3-phosphorylated inositol lipids, apoptosis, drug resistance, pharmacological inhibitors
Current Signal Transduction Therapy
Title: The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML)
Volume: 2 Issue: 3
Author(s): Alberto M. Martelli, Giovanna Tabellini, Roberta Bortul, Maria Nyakern, Pier Luigi Tazzari, Camilla Evangelisti and Lucio Cocco
Affiliation:
Keywords: Acute myeloid leukaemia, signal transduction, 3-phosphorylated inositol lipids, apoptosis, drug resistance, pharmacological inhibitors
Abstract: The PI3K/Akt signaling network regulates cell growth and apoptosis, and its constitutive activation has been implicated in the pathogenesis of a variety of malignancies. Recent studies suggest that PI3K/Akt signaling is frequently up-regulated in blast cells from AML patients and strongly contributes to proliferation, survival, and drug-resistance of these cells. Up-regulation of this network in AML may due to several reasons, including FLT3 and Ras activating mutations, increased levels of PI3K p110δ catalytic subunit, lack of PTEN lipid phosphatase expression, and autocrine production of growth factors. Small molecules designed to specifically target key components of this signal transduction network have been shown to induce apoptosis and/or increase conventional drug sensitivity of AML blasts in vitro. Therefore, these inhibitory molecules are being developed for clinical use either as single therapeutic agents or in combination with other forms of therapy. Nevertheless, PI3K/Akt blockade in vivo might have detrimental systemic side effects, given the multiple physiological roles played by this pathway, such as insulin-dependent glucose transport. Herein, we summarize our knowledge about PI3K/Akt signaling in AML and we highlight several pharmacological inhibitors which could be used in the future for treating this too often fatal hematological disorder.
Export Options
About this article
Cite this article as:
Martelli M. Alberto, Tabellini Giovanna, Bortul Roberta, Nyakern Maria, Tazzari Luigi Pier, Evangelisti Camilla and Cocco Lucio, The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML), Current Signal Transduction Therapy 2007; 2 (3) . https://dx.doi.org/10.2174/157436207781745373
DOI https://dx.doi.org/10.2174/157436207781745373 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Extracellular Production of the Oncolytic Enzyme, L-Asparaginase, by Newly Isolated Streptomyces sp. Strain NEAE-95 as Potential Microbial Cell Factories: Optimization of Culture Conditions Using Response Surface Methodology
Current Pharmaceutical Biotechnology TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies
Current Pharmaceutical Design Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism Sulfur Containing Acridine Derivatives in Preclinical Studies with Cancer Cell Lines
Current Medicinal Chemistry Energy Dependent Transport of Xenobiotics and Its Relevance to Multidrug Resistance
Current Cancer Drug Targets Heat Shock Protein 90 Inhibitors as Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design Proteomics in the Search for Biomarkers of Animal Cancer
Current Protein & Peptide Science Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Folate Receptor Targeted Liposomes Encapsulating Anti-Cancer Drugs
Current Pharmaceutical Biotechnology Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis
Current Pharmaceutical Design Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge
Current Cancer Drug Targets Hematopoietic Stem Cells: Transcriptional Regulation, Ex Vivo Expansion and Clinical Application
Current Molecular Medicine Induction and Escalation Therapies in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma
Current Cancer Drug Targets T Cell Redirecting Therapies for Cancer Treatment
Current Cancer Drug Targets Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Somatostatin and Octreotide on the Treatment of Acute Pancreatitis - Basic and Clinical Studies for Three Decades
Current Pharmaceutical Design